STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

News
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU shows positive results in Phase II trial for HER2-mutant lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
clinical trial
-
News
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Rhea-AI Summary
ENHERTU shows strong and durable tumor responses in patients with HER2 mutant non-small cell lung cancer. Objective response rates of 49% and 56% were observed with 5.4 mg/kg and 6.4 mg/kg doses, respectively. Median progression-free survival was 9.9 months at 5.4 mg/kg and 15.4 months at 6.4 mg/kg. Favorable safety profile supports the use of ENHERTU. No new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
clinical trial
-
News
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan shows positive initial results in lung cancer trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
Rhea-AI Summary
ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors and metastatic colorectal cancer. ENHERTU is jointly developed by Daiichi Sankyo and AstraZeneca. HER2 overexpression has been observed in 1% to 28% of metastatic solid tumors and in up to 5% of colorectal cancer patients. The BTDs are recognition of the potential of ENHERTU in these tumor types. ENHERTU has received a total of seven BTDs and has shown promising results in various trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
-
News
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
Rhea-AI Summary
AstraZeneca challenges drug price negotiation provisions of the Inflation Reduction Act (IRA) to protect access to medicines for rare diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
-
News
AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
Rhea-AI Summary
AstraZeneca presents data at the WCLC 2023 conference, showcasing the strength of its lung cancer portfolio. The FLAURA2 trial demonstrates the efficacy of TAGRISSO in combination with chemotherapy for EGFR-mutated lung cancer. ENHERTU, IMFINZI, and datopotamab deruxtecan also show promise in addressing unmet needs. AstraZeneca aims to have the right medicine for over half of lung cancer patients by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
News
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
Rhea-AI Summary
High-level results from the primary analysis of the DESTINY-PanTumor02 Phase II trial showed that ENHERTU demonstrated clinically meaningful progression-free survival and overall survival in previously treated patients with HER2-expressing advanced solid tumors. The trial also showed durable responses and reinforced results from an interim analysis presented at the ASCO Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
clinical trial
-
News
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Rhea-AI Summary
Topline results from the ongoing DESTINY-PanTumor02 phase 2 trial show that ENHERTU demonstrated clinically meaningful progression-free survival and overall survival in previously treated patients with HER2 expressing advanced solid tumors. The trial also showed durable responses and confirmed objective response rate. ENHERTU is a jointly developed drug by Daiichi Sankyo and AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
clinical trial
-
News
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
clinical trial
News
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
clinical trial
Stock AZN logo
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

#37 Ranked by Market Cap
#1673 Ranked by Stock Gains
#1215 Ranked by Dividends

AZN Stock Data

212.97B
1.54B
0.01%
16.8%
0.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.